Keyphrases
Stable Expression
100%
A1 Receptor
100%
Adeno-associated Virus Type 2
100%
Soluble Fms-like Tyrosine kinase-1 (sFlt-1)
100%
Antiangiogenic
100%
Cancer Gene Therapy
100%
Receptor 1
66%
Recombinant Adeno-associated Virus (rAAV)
66%
Tyrosine Kinase Receptor
66%
Immunohistochemistry
33%
Growth Inhibition
33%
Tumor Growth
33%
Gene Therapy
33%
Tumor Cells
33%
Transgenic
33%
In Situ Hybridization
33%
Disease-free Survival
33%
Angiogenesis
33%
Gene Transfer
33%
Solid Tumors
33%
Human Umbilical Vein Endothelial Cells (HUVECs)
33%
Adjuvant Therapy
33%
Tumor Metastasis
33%
Increased Dose
33%
Tumor Angiogenesis
33%
Sequester
33%
Therapeutic Effect
33%
Cell-free
33%
SKOV3
33%
Secretory Factors
33%
Tumor-free Survival
33%
Growth Index
33%
Tumor Invasion
33%
Vascular Endothelial Growth Factor
33%
Vascular Endothelial Growth Factor Receptor (VEGFR)
33%
Transgene Persistence
33%
Xenograft
33%
Long-term Expression
33%
Pharmacotherapy
33%
Endothelial Cell Proliferation
33%
Protein-based
33%
Human Ovarian Cancer Cell
33%
Implanted Tumor
33%
Antiangiogenic Activity
33%
Cell Proliferation Assay
33%
Hybrid Analysis
33%
Medicine and Dentistry
Receptor
100%
Protein Tyrosine Kinase
100%
Stable Expression
100%
Cancer Gene Therapy
100%
Antiangiogenic
100%
Adeno Associated Virus 2
100%
In Vitro
66%
Tyrosine Kinase Receptor
66%
Neoplasm
33%
Immunohistochemistry
33%
Drug Therapy
33%
Metastatic Carcinoma
33%
Tumor Cell
33%
Transgene
33%
Angiogenesis
33%
Solid Malignant Neoplasm
33%
Gene Therapy
33%
Ovarian Cancer Cell Line
33%
Heterodimer
33%
Xenograft
33%
Human Umbilical Vein Endothelial Cell
33%
Disease Free Survival
33%
Cell Proliferation Assay
33%
Vasculotropin Receptor
33%
Antiangiogenic Activity
33%
Gene Transfer
33%
Vasculotropin
33%
Therapy Effect
33%
Adjuvant Therapy
33%
Tumor Invasion
33%
Tumor Angiogenesis
33%
Tumor Progression
33%
In Situ Hybridization
33%
Biochemistry, Genetics and Molecular Biology
Stable Expression
100%
Receptor Tyrosine Kinase
100%
Tyrosine Kinase
100%
Tumor Gene
100%
Adeno Associated Virus 2
100%
Gene Therapy
100%
Angiogenesis
66%
Tyrosine Kinase Receptor
66%
Transgene
33%
Cancer Cell
33%
Tumor Progression
33%
Gene Therapy
33%
Transgenics
33%
Cell Proliferation
33%
Disease Free Survival
33%
Vascular Endothelial Growth Factor
33%
Antiangiogenic Activity
33%
VEGF Receptors
33%
In Situ Hybridization
33%
Drug Therapy
33%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Receptor
100%
Malignant Neoplasm
100%
Protein Tyrosine Kinase
100%
Adeno Associated Virus 2
100%
Antiangiogenic
100%
Tyrosine Kinase Receptor
66%
Tumor Growth
33%
Gene Delivery
33%
Disease Free Survival
33%
Solid Malignant Neoplasm
33%
Ovary Cancer
33%
Heterodimer
33%
Pharmacotherapy
33%
Therapeutic Effect
33%
Metastasis
33%
Vasculotropin
33%
Vasculotropin Receptor
33%
Tumor Invasion
33%